[{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||RAR-alpha","graph1":"Oncology","graph2":"Phase III","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"National Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Eureka Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Eureka Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Docetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"National Cancer Institute \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"National Cancer Institute \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sapience Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Collaboration","leadProduct":"ST101","moa":"C\/EBP-beta","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Sapience Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ Sapience Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"PDS Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"PDS0103","moa":"MUC1","graph1":"Oncology","graph2":"Preclinical","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ PDS Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"National Cancer Institute \/ PDS Biotechnology"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Elicio Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Elicio Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Propella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Abiraterone Decanoate","moa":"CYP17","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"National Cancer Institute \/ Propella Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Propella Therapeutics"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Pelcitoclax","moa":"||BCL-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Cancer Institute \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ Ascentage Pharma"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Navrogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Agreement","leadProduct":"NAV-001","moa":"MSLN","graph1":"Oncology","graph2":"IND Enabling","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Cancer Institute \/ Navrogen","highestDevelopmentStatusID":"5","companyTruncated":"National Cancer Institute \/ Navrogen"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Enzomenib","moa":"MLL-Menin interaction","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Cancer Institute \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"National Cancer Institute \/ National Cancer Institute"}]

Find Clinical Drug Pipeline Developments & Deals by National Cancer Institute

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The collaboration aims to evaluate DSP-5336 (enzomenib), an oral, small molecule designed to inhibit the menin and KMT2A protein interaction present in certain difficult to treat cancers.

                          Product Name : DSP-5336

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 14, 2025

                          Lead Product(s) : Enzomenib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Sumitomo Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under the licensing agreement, Eureka will develop and commercialize a novel antibody targeting MSLN, a potentially transformative T-cell therapy for solid tumors, in combination with ARTEMIS® T-cell receptor platform.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 14, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Eureka Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : NAV-001 targets tumors expressing the cancer antigen mesothelin, a cell surface protein over-expressed on various malignancies, including breast, colon, lung and mesothelioma cancers.

                          Product Name : NAV-001

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          July 11, 2022

                          Lead Product(s) : NAV-001

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Navrogen

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : A clinical trial has found that the combination of all-trans retinoic acid, which is a metabolite of vitamin A, and arsenic trioxide is highly effective in children with standard- and high-risk acute promyelocytic leukemia, or APL.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          December 11, 2021

                          Lead Product(s) : Arsenic Trioxide,Tretinoin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Ascentage Pharma and the NCI will collaborate on a series of clinical trials to evaluate the safety and efficacy of pelcitoclax, Ascentage Pharma's dual inhibitor of BCL-2 and BCL-xL proteins, in solid tumors based upon encouraging anti-tumor activity.

                          Product Name : APG-1252

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 19, 2021

                          Lead Product(s) : Pelcitoclax,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Ascentage Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : ST101, a first-in-class peptide antagonist of C/EBPβ, will be investigated for its impact on primary and metastatic cancer and the tumor microenvironment, leveraging NCI's expertise in C/EBP biology and genetic mouse models

                          Product Name : ST101

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          May 27, 2021

                          Lead Product(s) : ST101

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Sapience Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Under this new partnership, Propella and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.

                          Product Name : PRL-02

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 23, 2021

                          Lead Product(s) : Abiraterone Decanoate

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Propella Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          08

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : This expansion adds to the NCI’s ongoing evaluation of PDS0101 in combination with two separate immune-modulating agents, NHS-IL12 and M7824 to treat advanced HPV-associated cancers.

                          Product Name : PDS0103

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 29, 2020

                          Lead Product(s) : PDS0103

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : PDS Biotechnology

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : This collaborative study investigates the mechanism of action of ELI-002 in mice that have key human HLA genes important for immune response.

                          Product Name : ELI-002

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 16, 2020

                          Lead Product(s) : ELI-002

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Elicio Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : The NZ-DTX-001 study is a multi-center study including Karolinska University Hospital in Sweden, Herlev Hospital in Denmark, Kaunas University Hospital and Vilnius National Cancer Institute.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 19, 2020

                          Lead Product(s) : Docetaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank